Physician profile
Thomas Bailey Harper
NPI 1407858996
$503.72
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $168.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $122.01 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $82.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.69 | 2020 | |
| Csl Behring | $45.66 | 2019 | |
| Glaxosmithkline, LLC. | $33.71 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $29.18 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $28.60 | 2019 | |
| Genzyme Corporation | $23.35 | 2019 | |
| Kaleo, INC. | $22.37 | 2019 | |
| Genentech USA, INC. | $20.38 | 2019 | |
| Optinose US, INC. | $18.00 | 2019 | |
| Grifols USA, LLC | $15.53 | 2020 | |
| Mylan Specialty L.P. | $14.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.